Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Curr Neuropharmacol ; 2024 Feb 16.
Article in English | MEDLINE | ID: mdl-38549522

ABSTRACT

BACKGROUND: Environmental exposures to non-biodegradable and biodegradable plastics are unavoidable. Microplastics (MPs) and nanoplastics (NPs) from the manufacturing of plastics (primary sources) and the degradation of plastic waste (secondary sources) can enter the food chain directly or indirectly and, passing biological barriers, could target both the brain and the gonads. Hence, the worldwide diffusion of environmental plastic contamination (PLASTAMINATION) in daily life may represent a possible and potentially serious risk to human health. OBJECTIVE: This review provides an overview of the effects of non-biodegradable and the more recently introduced biodegradable MPs and NPs on the brain and brain-dependent reproductive functions, summarizing the molecular mechanisms and outcomes on nervous and reproductive organs. Data from in vitro, ex vivo, non-mammalian and mammalian animal models and epidemiological studies have been reviewed and discussed. RESULTS: MPs and NPs from non-biodegradable plastics affect organs, tissues and cells from sensitive systems such as the brain and reproductive organs. Both MPs and NPs induce oxidative stress, chronic inflammation, energy metabolism disorders, mitochondrial dysfunction and cytotoxicity, which in turn are responsible for neuroinflammation, dysregulation of synaptic functions, metabolic dysbiosis, poor gamete quality, and neuronal and reproductive toxicity. In spite of this mechanistic knowledge gained from studies of non-biodegradable plastics, relatively little is known about the adverse effects or molecular mechanisms of MPs and NPs from biodegradable plastics. CONCLUSION: The neurological and reproductive health risks of MPs/NPs exposure warrant serious consideration, and further studies on biodegradable plastics are recommended.

2.
Pharmaceutics ; 15(11)2023 Oct 28.
Article in English | MEDLINE | ID: mdl-38004530

ABSTRACT

Plastics have changed human lives, finding a broad range of applications from packaging to medical devices. However, plastics can degrade into microscopic forms known as micro- and nanoplastics, which have raised concerns about their accumulation in the environment but mainly about the potential risk to human health. Recently, biodegradable plastic materials have been introduced on the market. These polymers are biodegradable but also bioresorbable and, indeed, are fundamental tools for drug formulations, thanks to their transient ability to pass through biological barriers and concentrate in specific tissues. However, this "other side" of bioplastics raises concerns about their toxic potential, in the form of micro- and nanoparticles, due to easier and faster tissue accumulation, with unknown long-term biological effects. This review aims to provide an update on bioplastic-based particles by analyzing the advantages and drawbacks of their potential use as components of innovative formulations for brain diseases. However, a critical analysis of the literature indicates the need for further studies to assess the safety of bioplastic micro- and nanoparticles despite they appear as promising tools for several nanomedicine applications.

3.
Front Endocrinol (Lausanne) ; 14: 1269334, 2023.
Article in English | MEDLINE | ID: mdl-37900144

ABSTRACT

Introduction: Male reproduction is under the control of the hypothalamus-pituitary-gonadal (HPG) axis. The endocannabinoid system (ECS) and the kisspeptin system (KS) are two major signaling systems in the central and peripheral control of reproduction, but their possible interaction has been poorly investigated in mammals. This manuscript analyzes their possible reciprocal modulation in the control of the HPG axis. Materials and methods: Adolescent male rats were treated with kisspeptin-10 (Kp10) and endocannabinoid anandamide (AEA), the latter alone or in combination with the type 1 cannabinoid receptor (CB1) antagonist rimonabant (SR141716A). The hypothalamic KS system and GnRH expression, circulating sex steroids and kisspeptin (Kiss1) levels, and intratesticular KS and ECS were evaluated by immunohistochemical and molecular methods. Non-coding RNAs (i.e., miR145-5p, miR-132-3p, let7a-5p, let7b-5p) were also considered. Results: Circulating hormonal values were not significantly affected by Kp10 or AEA; in the hypothalamus, Kp10 significantly increased GnRH mRNA and aromatase Cyp19, Kiss1, and Kiss1 receptor (Kiss1R) proteins. By contrast, AEA treatment affected the hypothalamic KS at the protein levels, with opposite effects on the ligand and receptor, and SR141716A was capable of attenuating the AEA effects. Among the considered non-coding RNA, only the expression of miR145-5p was positively affected by AEA but not by Kp10 treatment. Localization of Kiss1+/Kiss1R+ neurons in the arcuate nucleus revealed an increase of Kiss1R-expressing neurons in Kp10- and AEA-treated animals associated with enlargement of the lateral ventricles in Kp10-treated animals. In the brain and testis, the selected non-coding RNA was differently modulated by Kp10 or AEA. Lastly, in the testis, AEA treatment affected the KS at the protein levels, whereas Kp10 affected the intragonadal levels of CB1 and FAAH, the main modulator of the AEA tone. Changes in pubertal transition-related miRNAs and the intratesticular distribution of Kiss1, Kiss1R, CB1, and CB2 following KP and AEA treatment corroborate the KS-ECS crosstalk also showing that the CB1 receptor is involved in this interplay. Conclusion: For the first time in mammals, we report the modulation of the KS in both the hypothalamus and testis by AEA and revealed the KP-dependent modulation of CB1 and FAAH in the testis. KP involvement in the progression of spermatogenesis is also suggested.


Subject(s)
Kisspeptins , MicroRNAs , Male , Rats , Animals , Kisspeptins/genetics , Kisspeptins/metabolism , Receptors, Kisspeptin-1/genetics , Endocannabinoids/pharmacology , Endocannabinoids/metabolism , Rimonabant/metabolism , Rimonabant/pharmacology , Hypothalamus/metabolism , Gonadotropin-Releasing Hormone/metabolism , Mammals/metabolism , Reproduction , RNA, Untranslated/metabolism , MicroRNAs/metabolism
4.
Article in English | MEDLINE | ID: mdl-36900934

ABSTRACT

INTRODUCTION: Few studies have focused on the long-term effects of the COVID-19 pandemic on mental health. The objective of our work was to evaluate the changes in emotional and behavioral symptoms in patients with neuropsychiatric disorders and the impact on parenting stress 1 year after the first national lockdown. METHODS: We enrolled 369 patients aged 1.5-18 years of age referred to the Child and Adolescent Neuropsychiatry Unit of the University Hospital of Salerno (Italy) by their parents. We asked their parents to complete two standardized questionnaires for the assessment of emotional/behavioral symptoms (Child Behavior CheckList, CBCL) and parental stress (Parenting Stress Index, PSI) prior to the pandemic (Time 0), during the first national lockdown (Time 1) and after 1 year (Time 2), and we monitored the changes in symptoms over time. RESULTS: After 1 year from the start of the first national lockdown, we found a significant increase of internalizing problems, anxiety, depression, somatization, and social and oppositional-defiant problems in older children (6-18 years), and a significant increase of somatization, anxiety problems, and sleep problems in younger children (1.5-5 years). We also observed a significant relationship between emotional/behavioral symptoms and parental stress. CONCLUSION: Our study showed that parental stress levels increased compared to the pre-pandemic months and continues to persist over time, while internalizing symptoms of children and adolescents showed a significant worsening during 1 year follow-up from the first COVID-19 lockdown.


Subject(s)
COVID-19 , Humans , Child , Adolescent , Infant , Child, Preschool , Pandemics , Follow-Up Studies , Communicable Disease Control , Parenting/psychology
5.
Cent Nerv Syst Agents Med Chem ; 22(3): 160-174, 2022.
Article in English | MEDLINE | ID: mdl-36177627

ABSTRACT

BACKGROUND: Neuroinflammation is a key component in the etiopathogenesis of neurological diseases and brain aging. This process involves the brain immune system that modulates synaptic functions and protects neurons from infection or damage. Hence, the knowledge of neuroinflammation related pathways and modulation by drugs or natural compounds is functional to developing therapeutic strategies aimed at preserving, maintaining and restoring brain health. OBJECTIVE: This review article summarizes the basics of neuroinflammation and related signaling pathways, the success of the dietary intervention in clinical practice and the possible development of RNA-based strategies for treating neurological diseases. METHODS: Pubmed search from 2012 to 2022 with the keywords neuroinflammation and molecular mechanisms in combination with diet, miRNA and non-coding RNA. RESULTS: Glial cells-play a crucial role in neuroinflammation, but several pathways can be activated in response to different inflammatory stimuli, inducing cell death by apoptosis, pyroptosis or necroptosis. The dietary intervention has immunomodulatory effects and could limit the inflammatory process induced by microglia and astrocytes. Thus by inhibiting neuroinflammation and improving the symptoms of a variety of neurological diseases, diet exerts pleiotropic neuroprotective effects independently from the spectrum of pathophysiological mechanisms underlying the specific disorder. Furthermore, data from animal models revealed that altered expression of specific noncoding RNAs, in particular microRNAs, contributes to neuroinflammatory diseases; consequently, RNA-based strategies may be promising to alleviate the consequences of neuroinflammation. CONCLUSION: Further studies are needed to identify the molecular pathways and the new pharmacological targets in neuroinflammation to lay the basis for more effective and selective therapies to be applied, in parallel to dietary intervention, in the treatment of neuroinflammation-based diseases.


Subject(s)
MicroRNAs , Nervous System Diseases , Neuroprotective Agents , Animals , Neuroinflammatory Diseases , Microglia/metabolism , Microglia/pathology , Astrocytes/metabolism , Neuroprotective Agents/pharmacology , MicroRNAs/genetics , Nervous System Diseases/metabolism , Inflammation/drug therapy , Inflammation/metabolism
6.
Genes (Basel) ; 13(2)2022 02 02.
Article in English | MEDLINE | ID: mdl-35205340

ABSTRACT

The hypothalamus-pituitary-testis axis controls the production of spermatozoa, and the kisspeptin system, comprising Kiss1 and Kiss1 receptor (Kiss1R), is the main central gatekeeper. The activity of the kisspeptin system also occurs in testis and spermatozoa, but currently the need of peripheral kisspeptin to produce gametes is not fully understood. Hence, we characterized kisspeptin system in rat spermatozoa and epididymis caput and cauda and analyzed the possible presence of Kiss1 in the epididymal fluid. The presence of Kiss1 and Kiss1R in spermatozoa collected from epididymis caput and cauda was evaluated by Western blot; significant high Kiss1 levels in the caput (p < 0.001 vs. cauda) and constant levels of Kiss1R proteins were observed. Immunofluorescence analysis revealed that the localization of Kiss1R in sperm head shifts from the posterior region in the epididymis caput to perforatorium in the epididymis cauda. In spermatozoa-free epididymis, Western blot revealed higher expression of Kiss1 and Kiss1R in caput (p < 0.05 vs. cauda). Moreover, immunohistochemistry revealed that Kiss1 and Kiss1R proteins were mainly localized in the secretory epithelial cell types and in contractile myoid cells, respectively. Finally, both dot blot and Elisa revealed the presence of Kiss1 in the epididymal fluid collected from epididymis cauda and caput, indicating that rat epididymis and spermatozoa possess a complete kisspeptin system. In conclusion, we reported for the first time in rodents Kiss1R trafficking in spermatozoa during the epididymis transit and Kiss1 measure in the epididymal fluid, thus suggesting a possible role for the system in spermatozoa maturation and storage within the epididymis.


Subject(s)
Epididymis , Kisspeptins , Animals , Epididymis/metabolism , Kisspeptins/genetics , Kisspeptins/metabolism , Male , Proteins/metabolism , Rats , Receptors, Kisspeptin-1/genetics , Receptors, Kisspeptin-1/metabolism , Sperm Maturation/genetics , Spermatozoa/metabolism
7.
Int J Mol Sci ; 22(22)2021 Nov 22.
Article in English | MEDLINE | ID: mdl-34830483

ABSTRACT

Glyphosate is widely used worldwide as a potent herbicide. Due to its ubiquitous use, it is detectable in air, water and foodstuffs and can accumulate in human biological fluids and tissues representing a severe human health risk. In plants, glyphosate acts as an inhibitor of the shikimate pathway, which is absent in vertebrates. Due to this, international scientific authorities have long-considered glyphosate as a compound that has no or weak toxicity in humans. However, increasing evidence has highlighted the toxicity of glyphosate and its formulations in animals and human cells and tissues. Thus, despite the extension of the authorization of the use of glyphosate in Europe until 2022, several countries have begun to take precautionary measures to reduce its diffusion. Glyphosate has been detected in urine, blood and maternal milk and has been found to induce the generation of reactive oxygen species (ROS) and several cytotoxic and genotoxic effects in vitro and in animal models directly or indirectly through its metabolite, aminomethylphosphonic acid (AMPA). This review aims to summarize the more relevant findings on the biological effects and underlying molecular mechanisms of glyphosate, with a particular focus on glyphosate's potential to induce inflammation, DNA damage and alterations in gene expression profiles as well as adverse effects on reproduction and development.


Subject(s)
Glycine/analogs & derivatives , Herbicides/adverse effects , Inflammation/genetics , Neoplasms/genetics , DNA Damage/drug effects , Europe , Gene Expression Regulation/drug effects , Glycine/adverse effects , Humans , Inflammation/chemically induced , Inflammation/pathology , Neoplasms/chemically induced , Neoplasms/pathology , Organophosphonates/metabolism , Reproduction/drug effects , Reproduction/genetics , Glyphosate
8.
Int J Mol Sci ; 22(18)2021 Sep 07.
Article in English | MEDLINE | ID: mdl-34575829

ABSTRACT

Bisphenol A (BPA) is largely used as a monomer in some types of plastics. It accumulates in tissues and fluids and is able to bypass the placental barrier, affecting various organs and systems. Due to huge developmental processes, children, foetuses, and neonates could be more sensitive to BPA-induced toxicity. To investigate the multi-systemic effects of chronic exposure to a low BPA dose (100 µg/L), pregnant Wistar rats were exposed to BPA in drinking water during gestation and lactation. At weaning, newborn rats received the same treatments as dams until sex maturation. Free and conjugated BPA levels were measured in plasma and adipose tissue; the size of cerebral ventricles was analysed in the brain; morpho-functional and molecular analyses were carried out in the liver with a focus on the expression of inflammatory cytokines and Sirtuin 1 (Sirt1). Higher BPA levels were found in plasma and adipose tissue from BPA treated pups (17 PND) but not in weaned animals. Lateral cerebral ventricles were significantly enlarged in lactating and weaned BPA-exposed animals. In addition, apart from microvesicular steatosis, liver morphology did not exhibit any statistically significant difference for morphological signs of inflammation, hypertrophy, or macrovesicular steatosis, but the expression of inflammatory cytokines, Sirt1, its natural antisense long non-coding RNA (Sirt1-AS LncRNA) and histone deacetylase 1 (Hdac1) were affected in exposed animals. In conclusion, chronic exposure to a low BPA dose could increase the risk for disease in adult life as a consequence of higher BPA circulating levels and accumulation in adipose tissue during the neonatal period.


Subject(s)
Benzhydryl Compounds/adverse effects , Drinking Water/chemistry , Environmental Exposure/adverse effects , Health Impact Assessment , Phenols/adverse effects , Water Pollutants, Chemical/adverse effects , Adipose Tissue/metabolism , Animals , Disease Models, Animal , Drinking Water/analysis , Female , Immunohistochemistry , Inflammation/etiology , Inflammation/metabolism , Inflammation/pathology , Lactation/drug effects , Liver/drug effects , Liver/metabolism , Liver/pathology , NAD/metabolism , Oxidative Stress , Pregnancy , Rats , Sirtuin 1/metabolism , Water Pollutants, Chemical/administration & dosage , Weaning
9.
Int J Mol Sci ; 22(2)2021 Jan 19.
Article in English | MEDLINE | ID: mdl-33478092

ABSTRACT

The endocannabinoid system (ECS) is a lipid cell signaling system involved in the physiology and homeostasis of the brain and peripheral tissues. Synaptic plasticity, neuroendocrine functions, reproduction, and immune response among others all require the activity of functional ECS, with the onset of disease in case of ECS impairment. Estrogens, classically considered as female steroid hormones, regulate growth, differentiation, and many other functions in a broad range of target tissues and both sexes through the activation of nuclear and membrane estrogen receptors (ERs), which leads to genomic and non-genomic cell responses. Since ECS function overlaps or integrates with many other cell signaling systems, this review aims at updating the knowledge about the possible crosstalk between ECS and estrogen system (ES) at both central and peripheral level, with focuses on the central nervous system, reproduction, and cancer.


Subject(s)
Central Nervous System/metabolism , Endocannabinoids/physiology , Estrogens/physiology , Animals , Central Nervous System/drug effects , Endocannabinoids/pharmacology , Estrogens/metabolism , Estrogens/pharmacology , Female , Humans , Neoplasms/metabolism , Neoplasms/pathology , Neuronal Plasticity/drug effects , Reproduction/drug effects , Reproduction/physiology , Signal Transduction/drug effects , Signal Transduction/physiology
10.
Rio de Janeiro; s.n; 2017. 116 p. graf, tab.
Thesis in Portuguese | LILACS | ID: biblio-983616

ABSTRACT

A infecção pelo HIV representa um grave problema de Saúde Pública e tem atingidode forma especial as mulheres, aumentando o risco de transmissão vertical (TV). Osurgimento de antirretrovirais mais potentes para o controle da TV trouxe forte impacto nasobrevida de crianças com essa infecção. Entretanto esses medicamentos podem levar aobaixo peso e à prematuridade nos bebês, comprometendo as condições de saúde dos recémnascidos.Objetivo. Determinar o peso ao nascer e mortalidade infantil, segundo o status deHIV da mãe, tratamento, e fatores sociodemográficos e clinico-obstétricos. Métodos. Foirealizado um estudo observacional de coorte retrospectiva de nascidos do município do Rio deJaneiro no período de 2007 a 2013, através das bases do SINAN, SINASC e SIM e para efeitode comparação entre a coorte de filhos de mães HIV+ e o conjunto dos filhos das mães HIVnascidosdo mesmo período foi utilizada a técnica de linkage. Para análise de dados foramutilizados os testes t-student, teste-U de Mann-Whitney e o teste de Kruskal-Wallis. Asdiferenças entre as proporções das variáveis categóricas foram avaliadas pelo teste quiquadrado de Pearson. Em todas as análises foi considerado um grau de significância de 5%.As magnitudes das associações entre status de infecção materna ao HIV e o baixo peso aonascer foram avaliadas pelo cálculo das Razões de Chances (RC) brutas e ajustadas,estimadas através da estatística de Regressão Logística Múltipla, com seus respectivosintervalos de confiança 95%. As estimativas do risco de óbito em 1 ano, segundo o status deHIV materno e status de BPN foram estimadas através do cálculo da mortalidade infantil.Todas as análises serão feitas utilizando o pacote estatístico SPSS (versão 20.0). Resultados.Filhos de mães HIV+ apresentaram uma chance de nascerem com BP 2,38 vezes maior,independentemente das demais variáveis...


HIV infection is a serious public health problem and has hit women in particular,increasing the risk of vertical transmission (TV). The emergence of more potentantiretrovirals for the control of the TV had a strong impact on the survival of children withthis infection. However, these medications can lead to low birth weight and prematurity,compromising the health of newborns. Goal. To determine birth weight and infant mortalityaccording to the mother's HIV status, treatment, and socio-demographic and clinical-obstetricfactors. Methods. An observational retrospective cohort study was carried out on the births ofthe city of Rio de Janeiro from 2007 to 2013, using the bases of SINAN, SINASC and SIMand for the comparison between the cohort of children of HIV + mothers and the set ofchildren Of the HIV-born mothers of the same period was used the linkage technique. Fordata analysis, the t-student, Mann-Whitney U-test and the Kruskal-Wallis test were used. Thedifferences between the proportions of the categorical variables were assessed by the Pearsonchi-square test. A significance level of 5% was considered in all analyzes. The magnitudes ofthe associations between maternal HIV infection status and low birth weight were assessed bycalculating the Gross and Adjusted Chances Ratios (RC), estimated through the MultipleLogistic Regression Statistics, with their respective 95% confidence intervals. Estimates ofdeath risk at 1 year, according to maternal HIV status and LBW status were estimated bycalculating infant mortality. All analyzes will be done using the SPSS statistical package(version 20.0). Results. Sons of HIV + mothers presented a chance of being born with BP2.38 times higher, independently of the other variables...


Subject(s)
Male , Female , Humans , Infant, Newborn , HIV Infections/mortality , HIV Infections/therapy , Infant Mortality , Infant, Low Birth Weight , Pregnant Women , Antiretroviral Therapy, Highly Active
11.
Neurobiol Aging ; 36(1): 492-504, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25085783

ABSTRACT

Amyotrophic lateral sclerosis (ALS) is a disease of variable severity in terms of speed of progression of the disease course. We found a similar variability in disease onset and progression of 2 familial ALS mouse strains, despite the fact that they carry the same transgene copy number and express the same amount of mutant SOD1G93A messenger RNA and protein in the central nervous system. Comparative analysis of 2 SOD1G93A mouse strains highlights differences associated with the disease severity that are unrelated to the degree of motor neuron loss but that appear to promote early dysfunction of these cells linked to protein aggregation. Features of fast progressing phenotype are (1) abundant protein aggregates containing mutant SOD1 and multiple chaperones; (2) low basal expression of the chaperone alpha-B-crystallin (CRYAB) and ß5 subunits of proteasome; and (3) downregulation of proteasome subunit expression at disease onset. In contrast, high levels of functional chaperones such as cyclophillin-A and CRYAB, combined with delayed alteration of expression of proteasome subunits and the sequestration of TDP43 into aggregates, are features associated with a more slowly progressing pathology. These data support the hypothesis that impairment of protein homeostasis caused by low-soluble chaperone levels, together with malfunction of the proteasome degradation machinery, contributes to accelerate motor neuron dysfunction and progression of disease symptoms. Therefore, modulating the activity of these systems could represent a rational therapeutic strategy for slowing down disease progression in SOD1-related ALS.


Subject(s)
Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/metabolism , Phenotype , Superoxide Dismutase/metabolism , Amyotrophic Lateral Sclerosis/pathology , Amyotrophic Lateral Sclerosis/therapy , Animals , Central Nervous System/metabolism , Cyclophilin A/metabolism , DNA-Binding Proteins/metabolism , Disease Models, Animal , Disease Progression , Mice, Transgenic , Molecular Chaperones , Molecular Targeted Therapy , Motor Neurons/pathology , Proteasome Endopeptidase Complex/genetics , Proteasome Endopeptidase Complex/metabolism , Protein Aggregation, Pathological/genetics , Protein Aggregation, Pathological/metabolism , RNA, Messenger/metabolism , Severity of Illness Index , Superoxide Dismutase/genetics
12.
Hum Mol Genet ; 24(7): 1843-55, 2015 Apr 01.
Article in English | MEDLINE | ID: mdl-25452428

ABSTRACT

Selenoprotein N (SEPN1) is a broadly expressed resident protein of the endoplasmic reticulum (ER) whose loss-of-function inexplicably leads to human muscle disease. We found that SEPN1 levels parallel those of endoplamic reticulum oxidoreductin 1 (ERO1), an ER protein thiol oxidase, and that SEPN1's redox activity defends the ER from ERO1-generated peroxides. Moreover, we have defined the redox-regulated interactome of SEPN1 and identified the ER calcium import SERCA2 pump as a redox-partner of SEPN1. SEPN1 enhances SERCA2 activity by reducing luminal cysteines that are hyperoxidized by ERO1-generated peroxides. Cells lacking SEPN1 are hypersensitive to ERO1 overexpression and conspicuously defective in ER calcium re-uptake. After being muscle-transduced with an adeno-associated virus driving ERO1α, SEPN1 knockout mice unmasks a myopathy that resembles the dense core disease due to human mutations in SEPN1, whereas the combined attenuation of ERO1α and SEPN1 enhances cell fitness. These observations reveal the involvement of SEPN1 in ER redox and calcium homeostasis and that an ERO1 inhibitor, restoring redox-dependent calcium homeostasis, may ameliorate the myopathy of SEPN1 deficiency.


Subject(s)
Endoplasmic Reticulum/metabolism , Muscle Proteins/metabolism , Muscle, Skeletal/metabolism , Muscular Diseases/metabolism , Sarcoplasmic Reticulum Calcium-Transporting ATPases/metabolism , Selenoproteins/metabolism , Animals , Cysteine/metabolism , Endoplasmic Reticulum/genetics , Humans , Mice , Mice, Knockout , Muscle Proteins/genetics , Muscle, Skeletal/pathology , Muscular Diseases/genetics , Muscular Diseases/pathology , Oxidation-Reduction , Oxidoreductases/genetics , Oxidoreductases/metabolism , Peroxides/metabolism , Sarcoplasmic Reticulum Calcium-Transporting ATPases/genetics , Selenoproteins/genetics
13.
Brain ; 136(Pt 11): 3305-32, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24065725

ABSTRACT

Amyotrophic lateral sclerosis is heterogeneous with high variability in the speed of progression even in cases with a defined genetic cause such as superoxide dismutase 1 (SOD1) mutations. We reported that SOD1(G93A) mice on distinct genetic backgrounds (C57 and 129Sv) show consistent phenotypic differences in speed of disease progression and life-span that are not explained by differences in human SOD1 transgene copy number or the burden of mutant SOD1 protein within the nervous system. We aimed to compare the gene expression profiles of motor neurons from these two SOD1(G93A) mouse strains to discover the molecular mechanisms contributing to the distinct phenotypes and to identify factors underlying fast and slow disease progression. Lumbar spinal motor neurons from the two SOD1(G93A) mouse strains were isolated by laser capture microdissection and transcriptome analysis was conducted at four stages of disease. We identified marked differences in the motor neuron transcriptome between the two mice strains at disease onset, with a dramatic reduction of gene expression in the rapidly progressive (129Sv-SOD1(G93A)) compared with the slowly progressing mutant SOD1 mice (C57-SOD1(G93A)) (1276 versus 346; Q-value ≤ 0.01). Gene ontology pathway analysis of the transcriptional profile from 129Sv-SOD1(G93A) mice showed marked downregulation of specific pathways involved in mitochondrial function, as well as predicted deficiencies in protein degradation and axonal transport mechanisms. In contrast, the transcriptional profile from C57-SOD1(G93A) mice with the more benign disease course, revealed strong gene enrichment relating to immune system processes compared with 129Sv-SOD1(G93A) mice. Motor neurons from the more benign mutant strain demonstrated striking complement activation, over-expressing genes normally involved in immune cell function. We validated through immunohistochemistry increased expression of the C3 complement subunit and major histocompatibility complex I within motor neurons. In addition, we demonstrated that motor neurons from the slowly progressing mice activate a series of genes with neuroprotective properties such as angiogenin and the nuclear factor (erythroid-derived 2)-like 2 transcriptional regulator. In contrast, the faster progressing mice show dramatically reduced expression at disease onset of cell pathways involved in neuroprotection. This study highlights a set of key gene and molecular pathway indices of fast or slow disease progression which may prove useful in identifying potential disease modifiers responsible for the heterogeneity of human amyotrophic lateral sclerosis and which may represent valid therapeutic targets for ameliorating the disease course in humans.


Subject(s)
Amyotrophic Lateral Sclerosis/genetics , Disease Progression , Motor Neurons/pathology , Superoxide Dismutase/genetics , Transcriptome/genetics , Amyotrophic Lateral Sclerosis/pathology , Animals , Disease Models, Animal , Female , Mice , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Transgenic , Motor Neurons/metabolism , Mutation/genetics , Phenotype , Superoxide Dismutase-1 , Time Factors
14.
PLoS One ; 8(7): e69540, 2013.
Article in English | MEDLINE | ID: mdl-23936040

ABSTRACT

Oxidative stress and mitochondrial impairment are the main pathogenic mechanisms of Amyotrophic Lateral Sclerosis (ALS), a severe neurodegenerative disease still lacking of effective therapy. Recently, the coenzyme-Q (CoQ) complex, a key component of mitochondrial function and redox-state modulator, has raised interest for ALS treatment. However, while the oxidized form ubiquinone10 was ineffective in ALS patients and modestly effective in mouse models of ALS, no evidence was reported on the effect of the reduced form ubiquinol10, which has better bioavailability and antioxidant properties. In this study we compared the effects of ubiquinone10 and a new stabilized formulation of ubiquinol10 on the disease course of SOD1(G93A) transgenic mice, an experimental model of fALS. Chronic treatments (800 mg/kg/day orally) started from the onset of disease until death, to mimic the clinical trials that only include patients with definite ALS symptoms. Although the plasma levels of CoQ10 were significantly increased by both treatments (from <0.20 to 3.0-3.4 µg/mL), no effect was found on the disease progression and survival of SOD1(G93A) mice. The levels of CoQ10 in the brain and spinal cord of ubiquinone10- or ubiquinol10-treated mice were only slightly higher (≤10%) than the endogenous levels in vehicle-treated mice, indicating poor CNS availability after oral dosing and possibly explaining the lack of pharmacological effects. To further examine this issue, we measured the oxidized and reduced forms of CoQ9/10 in the plasma, brain and spinal cord of symptomatic SOD1(G93A) mice, in comparison with age-matched SOD1(WT). Levels of ubiquinol9/10, but not ubiquinone9/10, were significantly higher in the CNS, but not in plasma, of SOD1(G93A) mice, suggesting that CoQ redox system might participate in the mechanisms trying to counteract the pathology progression. Therefore, the very low increases of CoQ10 induced by oral treatments in CNS might be not sufficient to provide significant neuroprotection in SOD1(G93A) mice.


Subject(s)
Amyotrophic Lateral Sclerosis/metabolism , Central Nervous System/metabolism , Ubiquinone/analogs & derivatives , Amyotrophic Lateral Sclerosis/blood , Amyotrophic Lateral Sclerosis/pathology , Animals , Brain/drug effects , Brain/metabolism , Brain/pathology , Central Nervous System/drug effects , Central Nervous System/pathology , Disease Models, Animal , Disease Progression , Humans , Mice , Mice, Transgenic , Spinal Cord/drug effects , Spinal Cord/metabolism , Spinal Cord/pathology , Superoxide Dismutase/metabolism , Ubiquinone/administration & dosage , Ubiquinone/blood , Ubiquinone/metabolism , Ubiquinone/pharmacology
15.
PLoS One ; 8(4): e61626, 2013.
Article in English | MEDLINE | ID: mdl-23620776

ABSTRACT

Amyotrophic lateral sclerosis (ALS) is a progressive fatal neurodegenerative disease characterised by loss of motor neurons that currently has no cure. Omega-3 polyunsaturated fatty acids, such as eicosapentaenoic acid (EPA), have many health benefits including neuroprotective and myoprotective potential. We tested the hypothesis that a high level of dietary EPA could exert beneficial effects in ALS. The dietary exposure to EPA (300 mg/kg/day) in a well-established mouse model of ALS expressing the G93A superoxide dismutase 1 (SOD1) mutation was initiated at a pre-symptomatic or symptomatic stage, and the disease progression was monitored until the end stage. Daily dietary EPA exposure initiated at the disease onset did not significantly alter disease presentation and progression. In contrast, EPA treatment initiated at the pre-symptomatic stage induced a significantly shorter lifespan. In a separate group of animals sacrificed before the end stage, the tissue analysis showed that the vacuolisation detected in G93A-SOD1 mice was significantly increased by exposure to EPA. Although EPA did not alter motor neurone loss, EPA reversed the significant increase in activated microglia and the astrocytic activation seen in G93A-SOD1 mice. The microglia in the spinal cord of G93A-SOD1 mice treated with EPA showed a significant increase in 4-hydroxy-2-hexenal, a highly toxic aldehydic oxidation product of omega-3 fatty acids. These data show that dietary EPA supplementation in ALS has the potential to worsen the condition and accelerate the disease progression. This suggests that great caution should be exerted when considering dietary omega-3 fatty acid supplements in ALS patients.


Subject(s)
Amyotrophic Lateral Sclerosis/pathology , Disease Progression , Eicosapentaenoic Acid/adverse effects , Administration, Oral , Amyotrophic Lateral Sclerosis/blood , Amyotrophic Lateral Sclerosis/physiopathology , Animals , Axons/drug effects , Axons/metabolism , Axons/pathology , Dietary Supplements , Disease Models, Animal , Eicosapentaenoic Acid/administration & dosage , Eicosapentaenoic Acid/blood , Female , Humans , Lipid Metabolism/drug effects , Lipid Peroxidation/drug effects , Mice , Mice, Inbred C57BL , Mice, Transgenic , Motor Activity/drug effects , Motor Neurons/drug effects , Motor Neurons/metabolism , Motor Neurons/pathology , Mutant Proteins/metabolism , Neuroglia/drug effects , Neuroglia/metabolism , Neuroglia/pathology , Spinal Cord/drug effects , Spinal Cord/pathology , Spinal Cord/physiopathology , Superoxide Dismutase/genetics , Superoxide Dismutase/metabolism , Superoxide Dismutase-1 , Survival Analysis , Tyrosine/analogs & derivatives , Tyrosine/metabolism , Vacuoles/drug effects , Vacuoles/metabolism
16.
Prog Neurobiol ; 97(2): 101-26, 2012 May.
Article in English | MEDLINE | ID: mdl-22033150

ABSTRACT

The ubiquitin-proteasome system (UPS) is the major intracellular proteolytic mechanism controlling the degradation of misfolded/abnormal proteins. A common hallmark in amyotrophic lateral sclerosis (ALS) and in other neurodegenerative disorders is the accumulation of misfolded/abnormal proteins into the damaged neurons, leading to the formation of cellular inclusions that are mostly ubiquitin-positive. Although proteolysis is a complex mechanism requiring the participation of different pathways, the abundant accumulation of ubiquitinated proteins strongly suggests an important contribution of UPS to these neuropathological features. The use of cellular and animal models of ALS, particularly those expressing mutant SOD1, the gene mutation most represented in familiar ALS, has provided significant evidence for a role of UPS in protein inclusions formation and motor neuron death. This review will specifically discuss this piece of evidence and provide suggestions of potential strategies for therapeutic intervention. We will also discuss the finding that, unlike the constitutive proteasome subunits, the inducible subunits are overexpressed early during disease progression in SOD1 mice models of ALS. These subunits form the immunoproteasome and generate peptides for the major histocompatibility complex class I molecules, suggesting a role of this system in the immune responses associated with the pathological features of ALS. Since recent discoveries indicate that innate and adaptive immunity may influence the disease process, in this review we will also provide evidence of a possible connection between immune-inflammatory reactions and UPS function, in the attempt to better understand the etiopathology of ALS and to identify appropriate targets for novel treatment strategies of this devastating disease.


Subject(s)
Amyotrophic Lateral Sclerosis/immunology , Amyotrophic Lateral Sclerosis/metabolism , Immunity/physiology , Proteasome Endopeptidase Complex/metabolism , Ubiquitin/metabolism , Amyotrophic Lateral Sclerosis/genetics , Animals , Humans , Inflammation , Mice , Proteasome Endopeptidase Complex/genetics , Protein Folding , Superoxide Dismutase/genetics , Superoxide Dismutase/metabolism , Superoxide Dismutase-1 , Ubiquitin/genetics
17.
Hum Mol Genet ; 19(17): 3440-56, 2010 Sep 01.
Article in English | MEDLINE | ID: mdl-20570967

ABSTRACT

Several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), are characterized by the presence of misfolded proteins, thought to trigger neurotoxicity. Some familial forms of ALS (fALS), clinically indistinguishable from sporadic ALS (sALS), are linked to superoxide dismutase 1 (SOD1) gene mutations. It has been shown that the mutant SOD1 misfolds, forms insoluble aggregates and impairs the proteasome. Using transgenic G93A-SOD1 mice, we found that spinal cord motor neurons, accumulating mutant SOD1 also over-express the small heat shock protein HspB8. Using motor neuronal fALS models, we demonstrated that HspB8 decreases aggregation and increases mutant SOD1 solubility and clearance, without affecting wild-type SOD1 turnover. Notably, HspB8 acts on mutant SOD1 even when the proteasome activity is specifically blocked. The pharmacological blockage of autophagy resulted in a dramatic increase of mutant SOD1 aggregates. Immunoprecipitation studies, performed during autophagic flux blockage, demonstrated that mutant SOD1 interacts with the HspB8/Bag3/Hsc70/CHIP multiheteromeric complex, known to selectively activate autophagic removal of misfolded proteins. Thus, HspB8 increases mutant SOD1 clearance via autophagy. Autophagy activation was also observed in lumbar spinal cord of transgenic G93A-SOD1 mice since several autophago-lysosomal structures were present in affected surviving motor neurons. Finally, we extended our observation to a different ALS model and demonstrated that HspB8 exerts similar effects on a truncated version of TDP-43, another protein involved both in fALS and in sALS. Overall, these results indicate that the pharmacological modulation of HspB8 expression in motor neurons may have important implications to unravel the molecular mechanisms involved both in fALS and in sALS.


Subject(s)
Amyotrophic Lateral Sclerosis/metabolism , Amyotrophic Lateral Sclerosis/physiopathology , Autophagy , HSP20 Heat-Shock Proteins/metabolism , Heat-Shock Proteins/metabolism , Muscle Proteins/metabolism , Protein Serine-Threonine Kinases/metabolism , Superoxide Dismutase/metabolism , Amyotrophic Lateral Sclerosis/genetics , Animals , Cell Line , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Female , HSP20 Heat-Shock Proteins/genetics , Heat-Shock Proteins/genetics , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Molecular Chaperones , Motor Neurons/metabolism , Muscle Proteins/genetics , Protein Folding , Protein Serine-Threonine Kinases/genetics , Superoxide Dismutase/chemistry , Superoxide Dismutase/genetics , Superoxide Dismutase-1
18.
PLoS One ; 4(12): e8130, 2009 Dec 02.
Article in English | MEDLINE | ID: mdl-19956584

ABSTRACT

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a progressive and fatal motor neuron disease, and protein aggregation has been proposed as a possible pathogenetic mechanism. However, the aggregate protein constituents are poorly characterized so knowledge on the role of aggregation in pathogenesis is limited. METHODOLOGY/PRINCIPAL FINDINGS: We carried out a proteomic analysis of the protein composition of the insoluble fraction, as a model of protein aggregates, from familial ALS (fALS) mouse model at different disease stages. We identified several proteins enriched in the detergent-insoluble fraction already at a preclinical stage, including intermediate filaments, chaperones and mitochondrial proteins. Aconitase, HSC70 and cyclophilin A were also significantly enriched in the insoluble fraction of spinal cords of ALS patients. Moreover, we found that the majority of proteins in mice and HSP90 in patients were tyrosine-nitrated. We therefore investigated the role of nitrative stress in aggregate formation in fALS-like murine motor neuron-neuroblastoma (NSC-34) cell lines. By inhibiting nitric oxide synthesis the amount of insoluble proteins, particularly aconitase, HSC70, cyclophilin A and SOD1 can be substantially reduced. CONCLUSION/SIGNIFICANCE: Analysis of the insoluble fractions from cellular/mouse models and human tissues revealed novel aggregation-prone proteins and suggests that nitrative stress contribute to protein aggregate formation in ALS.


Subject(s)
Amyotrophic Lateral Sclerosis/pathology , Detergents/pharmacology , Proteins/chemistry , Proteins/metabolism , Stress, Physiological/drug effects , Tyrosine/analogs & derivatives , Aconitate Hydratase/metabolism , Aconitate Hydratase/ultrastructure , Amino Acid Substitution/genetics , Amyotrophic Lateral Sclerosis/enzymology , Animals , Disease Models, Animal , Disease Progression , Electrophoresis, Gel, Two-Dimensional , Humans , Immunohistochemistry , Mice , NG-Nitroarginine Methyl Ester/pharmacology , Protein Structure, Quaternary , Proteomics , Reproducibility of Results , Solubility/drug effects , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Spinal Cord/drug effects , Spinal Cord/ultrastructure , Superoxide Dismutase/metabolism , Superoxide Dismutase-1 , Tyrosine/metabolism
19.
Hum Mol Genet ; 18(1): 82-96, 2009 Jan 01.
Article in English | MEDLINE | ID: mdl-18826962

ABSTRACT

In familial and sporadic amyotrophic lateral sclerosis (ALS) and in rodent models of the disease, alterations in the ubiquitin-proteasome system (UPS) may be responsible for the accumulation of potentially harmful ubiquitinated proteins, leading to motor neuron death. In the spinal cord of transgenic mice expressing the familial ALS superoxide dismutase 1 (SOD1) gene mutation G93A (SOD1G93A), we found a decrease in constitutive proteasome subunits during disease progression, as assessed by real-time PCR and immunohistochemistry. In parallel, an increased immunoproteasome expression was observed, which correlated with a local inflammatory response due to glial activation. These findings support the existence of proteasome modifications in ALS vulnerable tissues. To functionally investigate the UPS in ALS motor neurons in vivo, we crossed SOD1G93A mice with transgenic mice that express a fluorescently tagged reporter substrate of the UPS. In double-transgenic Ub(G76V)-GFP /SOD1G93A mice an increase in Ub(G76V)-GFP reporter, indicative of UPS impairment, was detectable in a few spinal motor neurons and not in reactive astrocytes or microglia, at symptomatic stage but not before symptoms onset. The levels of reporter transcript were unaltered, suggesting that the accumulation of Ub(G76V)-GFP was due to deficient reporter degradation. In some motor neurons the increase of Ub(G76V)-GFP was accompanied by the accumulation of ubiquitin and phosphorylated neurofilaments, both markers of ALS pathology. These data suggest that UPS impairment occurs in motor neurons of mutant SOD1-linked ALS mice and may play a role in the disease progression.


Subject(s)
Amyotrophic Lateral Sclerosis/metabolism , Motor Neurons/metabolism , Proteasome Endopeptidase Complex/metabolism , Superoxide Dismutase/metabolism , Ubiquitin/metabolism , Animals , Cells, Cultured , Disease Models, Animal , Female , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Mutation, Missense , Proteasome Endopeptidase Complex/genetics , Spinal Cord/metabolism , Superoxide Dismutase/genetics , Superoxide Dismutase-1 , Ubiquitin/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...